title: Labetalol for hypertension in pregnancy.
abstract: BACKGROUND
  Labetalol is one of the most commonly used antihypertensive medications for the treatment of hypertension during pregnancy, an increasingly common and leading cause of maternal mortality and morbidity worldwide.
  
  
  METHODS
  The literature reviewed included the 2014 Canadian national pregnancy hypertension guideline and its references. The additional published literature was retrieved through searches of Medline, CINAHL, and The Cochrane Library using appropriate controlled vocabulary (e.g., pregnancy, hypertension, pre-eclampsia, pregnancy toxemias) and key words (e.g., diagnosis, evaluation, classification, prediction, prevention, prognosis, treatment, and postpartum follow-up).Results were restricted to systematic reviews, randomized controlled trials, controlled clinical trials, and observational studies published in French or English, Jan-Mar/14. The unpublished literature was identified by searching websites of health technology assessment and health technology-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. We evaluated the impact of interventions on substantive clinical outcomes for mothers and babies.
  
  
  CONCLUSIONS
  Labetalol is a reasonable choice for treatment of severe or non-severe hypertension in pregnancy. However, we should continue our search for other therapeutic options.
authors.affiliation: University of British Columbia, BC Women's Hospital and Health Centre , 4500 Oak Street, Room 1U59, Vancouver, BC V6H 3N1 , Canada +1 604 875 3054; +1 604 875 2424; Ext: 6012 ; +1 604 875 3212 ; LMagee@cw.bc.ca.
authors.forename: Laura A
authors.initials: LA
authors.lastname: Magee
authors.forename: Shirin
authors.initials: S
authors.lastname: Namouz-Haddad
authors.forename: Vivien
authors.initials: V
authors.lastname: Cao
authors.forename: Gideon
authors.initials: G
authors.lastname: Koren
authors.forename: Peter
authors.initials: P
authors.lastname: von Dadelszen
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002170:Canada; D005260:Female; D006801:Humans; D046110:Hypertension, Pregnancy-Induced / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D007741:Labetalol / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011256:Pregnancy Outcome; D011379:Prognosis; D012720:Severity of Illness Index
chemical_list: D000959:Antihypertensive Agents; D007741:Labetalol
keywords: hypertension; labetalol; pre-eclampsia; pregnancy